Silence Therapeutics plc (SLNCF)

I Emailed Silence Therapeutics about SLN 360.
I texted Silence Therapeutics about SLN 360.
I did my best to contact upper management regarding SLN 360.
The company failed to respond to all my efforts.
I had to ask myself, could they have not at least responded?
So now I will make every effort to find out if they can help.
Below is what I had Emailed and texted to Silence Therapeutics
management. Why have they not answered my simple questions?

Dear Sirs,

In your recent clinical trials for SLN 360 the press release stated the trial was conducted in healthy adults with high Lp(a).
Can you please clarify and elaborate on the word health adults. Did these people in the trials have a history of genetically
inherited familial hypercholesterolemia? My fiancé is suffering from a very high familial hypercholesterolemia, very high numbers on her Lp(a), and so we need to know whether
or not to somehow get in contact with your upcoming clinical trial, if it includes people with familial hypercholesterolemia?
My fiancé is fifty years old, and so we are very concerned, and it is in a way an emergency that if possible she can be included in your next clinical trial.
Also her older brother has the same infliction.
Thank you very much.

Sincerely

Shanghai’s Hansoh inks development deal with UK biotech
For the second time this week, Chinese biotech Hansoh made a deal. This time, the $1 billion+ deal is with the London-based  siRNA firm Silence Therapeutics.

The two companies announced a collaboration today to develop siRNAs for three undisclosed targets, leveraging Silence’s mRNAi platform. Hansoh will pay Silence $16 million upfront, with a potential $1.3 billion more in additional milestones plus royalties on net product sales.

Hansoh will have the exclusive option to license rights to the first two targets in China, Hong Kong, Macau and Taiwan following the completion of Phase I studies. Silence will retain exclusive rights for those two targets in all other markets, maintaining responsibility for all activities until Hansoh exercises its option.

Silence will also retain responsibility for development outside those Asian markets after the Phase I studies are complete.

Hansoh will also have the exclusive option to license global rights for a third target at the point of IND filing, maintaining responsibility for all development activities after exercising that option.

“We are excited to partner with Silence, a pioneer in siRNA therapeutic development with decades of scientific and technical experience,” said executive director of Hansoh’s board Eliza Sun in a statement.